Simultaneous Detection of Drug-Induced Liver Injury Protein and microRNA Biomarkers Using Dynamic Chemical Labelling on a Luminex MAGPIX System

Antonio Marín-Romero, Mavys Tabraue-Chávez, Barbara López-Longarela, Mario A. Fara, Rosario M. Sánchez-Martín, James W Dear, Hugh Ilyine, Juan J. Díaz-Mochón*, Salvatore Pernagallo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Drug-Induced Liver Injury (DILI) is a potentially fatal adverse event and a leading cause
for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now rec-
ommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury
and inform about mechanistic basis. This manuscript describes the development of seqCOMBO, a
unique combo-multiplexed assay which combines the dynamic chemical labelling approach and an
antibody dependant method on Luminex MAGPIX system. SeqCOMBO enables a versatile multi-
plexing platform to perform qualitative and quantitative analysis of proteins and miRNAs in patient
serum samples simultaneously. To the best of our knowledge, this is the first method to profile
protein and miRNA biomarkers to diagnose DILI in a single step assay.
Original languageEnglish
JournalAnalytica
DOIs
Publication statusPublished - 3 Oct 2021

Keywords / Materials (for Non-textual outputs)

  • dynamic chemical labelling (DCL)
  • drug-induced liver injury (DILI)
  • miRNA-122
  • Luminex MAGPIX
  • Liquid Biopsy
  • antibody-dependant method

Fingerprint

Dive into the research topics of 'Simultaneous Detection of Drug-Induced Liver Injury Protein and microRNA Biomarkers Using Dynamic Chemical Labelling on a Luminex MAGPIX System'. Together they form a unique fingerprint.

Cite this